Nightingale Health

3.02

EUR

-0.66 %

Corporate customer

HEALTH

First North Finland

Medical Equipment & Services

Health Care

4,529 following

-0.66%

+4.86%

+3.42%

-4.43%

+51%

+141.99%

-17.85%

-

-41.36%

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Market cap

184M EUR

Turnover

108.55K EUR

P/E (adj.) (25e)

-10.85

EV/EBIT (adj.) (25e)

-7.35

P/B (25e)

2.67

EV/S (25e)

20.09

Dividend yield-% (25e)

-

Coverage

Recommendation

Reduce

Target price

2.90 EUR

Updated

23.09.2024

Latest research

Latest analysis report

Released: 23.09.2024

Latest extensive report

Released: 05.06.2023

Financial calendar

6.3

2025

Interim report Q2'25

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Regulatory press release12/23/2024, 12:00 PM

Conversion of Nightingale Health Plc's EMP shares to Series B shares

Nightingale Health

Regulatory press release12/20/2024, 3:35 PM

Nightingale Health Plc - Managers' Transactions - Olli Karhi

Nightingale Health

Regulatory press release12/18/2024, 7:35 PM

Nightingale Health Plc appoints Lago Kapital as liquidity provider

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/13/2024, 1:50 PM

Nightingale Health Plc: Subscription of Series B shares with option rights

Nightingale Health

Press release12/4/2024, 8:00 AM

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Nightingale Health

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Analyst Comment11/29/2024, 11:06 AM by

Nightingale opens Singapore laboratory

According to the release, the opening of the laboratory will be celebrated on Monday, December 2, and the company expects the first healthcare samples to arrive at the laboratory during Q1/2025.

Nightingale Health

Press release11/29/2024, 9:30 AM

Nightingale Health announces opening of its Singapore laboratory

Nightingale Health

Analyst Comment11/27/2024, 1:57 PM by

Nightingale explores transfer to Nasdaq Helsinki main list and OTC trading in the US

With the possible transfer and OTC cross-trading, the company aims, among other things, to improve the liquidity of the stock and to broaden its international shareholder base.

Nightingale Health

Regulatory press release11/27/2024, 12:20 PM

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.

Nightingale Health

Analyst Comment11/14/2024, 8:44 AM by

Nightingale completes necessary regulatory approvals in Singapore

According to the release, Nightingale's Singaporean subsidiary was granted ISO 13485:2016 certification, the final approval needed to begin operations in Singapore. The company says it is now ready to launch its blood testing service in Singapore before the end of the year.

Nightingale Health

Press release11/14/2024, 7:15 AM

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore

Nightingale Health

Nightingale Health AGM | CEO's review 8.11.2024

Video11/11/2024, 12:53 PM

Nightingale Health AGM | CEO's review 8.11.2024

Review by CEO Teemu Suna from Nightingale Health's Annual General Meeting on November 8, 2024.

Nightingale Health

Regulatory press release11/8/2024, 3:00 PM

Resolutions of the Annual General Meeting and the Board of Directors' organizational meeting of Nightingale Health Plc

Nightingale Health

Press release11/6/2024, 7:45 AM

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health

Analyst Comment10/30/2024, 9:38 AM by

Nightingale and Boston Heart move from pilot to broader collaboration

According to the stock exchange release, the pilot announced by Nightingale and Boston Heart in June has been successfully completed. The companies have now signed an agreement to start providing Nightingale's blood test-based Health Check to Boston Heart's customers.

Nightingale Health

Press release10/30/2024, 7:35 AM

Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale's Health Check in the US

Nightingale Health

Regulatory press release10/10/2024, 10:00 AM

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health

Regulatory press release10/10/2024, 6:00 AM

Nightingale Health's Annual Report for financial year 2023-2024 has been published

Nightingale Health

Regulatory press release10/9/2024, 11:30 AM

Conversion of Nightingale Health Plc's Series A shares to Series B shares

Nightingale Health

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.